Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Kovitz Investment Group Partners LLC

Kovitz Investment Group Partners LLC reduced its holdings in shares of Moderna, Inc. (NASDAQ:MRNAFree Report) by 4.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 38,044 shares of the company’s stock after selling 1,627 shares during the period. Kovitz Investment Group Partners LLC’s holdings in Moderna were worth $3,930,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Norges Bank purchased a new stake in shares of Moderna in the 4th quarter valued at approximately $628,359,000. Renaissance Technologies LLC increased its position in shares of Moderna by 108.2% in the 1st quarter. Renaissance Technologies LLC now owns 3,818,180 shares of the company’s stock valued at $657,720,000 after purchasing an additional 1,984,458 shares during the last quarter. Morgan Stanley increased its position in shares of Moderna by 19.1% in the 4th quarter. Morgan Stanley now owns 4,187,353 shares of the company’s stock valued at $752,133,000 after purchasing an additional 670,284 shares during the last quarter. Barclays PLC increased its position in shares of Moderna by 84.1% in the 2nd quarter. Barclays PLC now owns 910,892 shares of the company’s stock valued at $110,677,000 after purchasing an additional 416,095 shares during the last quarter. Finally, Invesco Ltd. increased its position in shares of Moderna by 21.1% in the 1st quarter. Invesco Ltd. now owns 2,128,252 shares of the company’s stock valued at $366,611,000 after purchasing an additional 371,311 shares during the last quarter. 64.51% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

MRNA has been the topic of a number of recent analyst reports. The Goldman Sachs Group dropped their price objective on shares of Moderna from $269.00 to $231.00 and set a “buy” rating on the stock in a research report on Friday, November 3rd. TheStreet cut shares of Moderna from a “c” rating to a “d” rating in a report on Thursday, November 2nd. Deutsche Bank Aktiengesellschaft cut shares of Moderna from a “hold” rating to a “sell” rating and lowered their target price for the company from $125.00 to $60.00 in a report on Thursday, November 2nd. Royal Bank of Canada restated an “outperform” rating and issued a $125.00 target price on shares of Moderna in a report on Friday, January 12th. Finally, HSBC upgraded shares of Moderna from a “reduce” rating to a “hold” rating and lowered their target price for the company from $89.00 to $69.00 in a report on Friday, November 3rd. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $123.96.

Read Our Latest Analysis on Moderna

Moderna Stock Down 6.7 %

Shares of NASDAQ:MRNA opened at $87.41 on Friday. The stock has a market cap of $33.33 billion, a P/E ratio of -9.35 and a beta of 1.69. The firm has a fifty day moving average price of $96.62 and a 200 day moving average price of $96.00. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.46 and a quick ratio of 2.35. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $177.37.

Insider Buying and Selling

In other Moderna news, insider Arpa Garay sold 564 shares of the company’s stock in a transaction on Wednesday, December 6th. The shares were sold at an average price of $78.34, for a total transaction of $44,183.76. Following the completion of the transaction, the insider now owns 3,690 shares in the company, valued at approximately $289,074.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Moderna news, insider Arpa Garay sold 564 shares of the company’s stock in a transaction on Wednesday, December 6th. The shares were sold at an average price of $78.34, for a total transaction of $44,183.76. Following the completion of the transaction, the insider now owns 3,690 shares in the company, valued at approximately $289,074.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, President Stephen Hoge sold 45,000 shares of the company’s stock in a transaction on Wednesday, December 27th. The stock was sold at an average price of $100.01, for a total transaction of $4,500,450.00. Following the transaction, the president now owns 1,531,063 shares of the company’s stock, valued at approximately $153,121,610.63. The disclosure for this sale can be found here. Insiders sold a total of 106,899 shares of company stock worth $10,732,838 in the last 90 days. Company insiders own 15.70% of the company’s stock.

About Moderna

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Further Reading

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNAFree Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.